https://doi.org/10.55788/1cddd96e
The primary results of the CEASE-AF trial demonstrated that hybrid ablation, epicardial plus endocardial ablation, was superior to endocardial ablation alone in reducing atrial arrhythmias in patients with persistent and longstanding persistent atrial fibrillation (AF), without increasing adverse events.
The prospective CEASE-AF trial (NCT02695277) randomised 170 patients with persistent AF and enlarged left atria or longstanding persistent AF 2:1 to hybrid ablation or endocardial catheter ablation [1]. In the hybrid ablation arm, patients first underwent epicardial ablation, followed by a 90-day blanking period and subsequent endocardial ablation. The primary efficacy outcome was the freedom from AF, atrial flutter, or atrial tachycardia >30 seconds through 12 months. Prof. Nicolas Doll (Georg-August University, Germany) presented the primary results of the trial.
The primary endpoint was reached by 71.6% of the participants in the hybrid arm and by 39.2% of the participants in the endocardial ablation arm, representing a significant difference in efficacy between the 2 study arms (P<0.001). Furthermore, the rates of ‘repeat ablations’ (4.2% vs 35.3%; P<0.001) and cardioversions (11.6% vs 25.5%; P=0.037) were lower in the intervention arm. Notably, no significant difference was observed in terms of safety: the composite complication rate at 30 days post-index and 30 days post-second stage plus repeat ablation were 7.8% in the intervention arm and 5.8% in the control arm (P=0.75). Prof. Doll stressed that the success of an epicardial-endocardial approach emphasises the role of a collaborative heart team approach in the treatment of non-paroxysmal AF.
-
- Doll N, et al. Effectiveness and safety of hybrid epicardial and endocardial ablation versus endocardial ablation in patients with persistent and longstanding persistent atrial fibrillation: primary results of the CEASE-AF trial. Late-Breaking Science Day 2, EHRA 2023, 16–18 April, Barcelona, Spain.
Copyright ©2023 Medicom Medical Publishers
Posted on
« Promising results for Marshall Plan ablation strategy Next Article
Early or delayed ablation for AF? »
Table of Contents: EHRA 2023
Featured articles
CEASE-AF meets primary endpoint in persistent AF
ANTWERP score selects HF patients for AF ablation
Ablation for Atrial Fibrillation
Surgery saves lives in patients with oesophageal fistula
MANIFEST-PF: Good results for the pentaspline PFA catheter
POWER FAST III: High-power, short-duration radiofrequency ablation for AF
High-power, short-duration ablation linked to a higher stroke risk
Early or delayed ablation for AF?
CEASE-AF meets primary endpoint in persistent AF
Promising results for Marshall Plan ablation strategy
Updates on Devices
Can ICD-EG-derived information improve ventricular tachycardia ablation outcomes?
Prolonged ECG monitoring detects relevant arrhythmias in HCM
Does adaptive pacing work in patients with HF, LBBB, and intact AV conduction?
Can we identify patients who may not benefit from ICD therapy?
Miscellaneous
Statins display benefits for AF patients in a large population-based study
ANTWERP score selects HF patients for AF ablation
Epicardial ablation successful in Brugada syndrome
Highly increased risk of arrhythmias after mechanical ventilation for COVID-19
Related Articles
COVI-PRONE trial on its back
High COVID-19 mortality in Swiss cancer patients
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy